Overview
- Amneal said it reached a definitive deal to buy Kashiv BioSciences for about $1.1 billion, with $375 million in cash and $375 million in stock at closing plus potential milestone payments.
- The companies said the deal still needs Amneal shareholder approval and regulatory clearance, with closing targeted for the second half of 2026.
- Alongside the announcement, Amneal posted unaudited first‑quarter 2026 results and raised its full‑year outlook before an 8:30 a.m. ET investor call.
- Amneal said the purchase creates a larger biosimilars platform that can pursue a $300 billion‑plus market as many biologic drugs lose exclusivity.
- Named advisors include Goldman Sachs for the board’s independent committee, Simpson Thacher for Amneal, and J.P. Morgan and Holland & Knight for Kashiv, with proxy and SEC filings to come.